Remus Pharmaceuticals Limited (NSE:REMUS)
India · Delayed Price · Currency is INR 714.00
-25.50 (-3.45%)
May 27, 2026, 3:29 PM IST
Remus Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Remus Pharmaceuticals had annual revenue of 8.54B INR with 37.60% growth. Remus Pharmaceuticals had revenue of 4.53B in the half year ending March 31, 2026, with 146.57% growth.
Revenue
8.54B
Revenue Growth
+37.60%
P/S Ratio
0.97
Revenue / Employee
125.54M
Employees
68
Market Cap
8.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.54B | 2.33B | 37.60% |
| Mar 31, 2025 | 6.20B | 4.07B | 191.33% |
| Mar 31, 2024 | 2.13B | 1.68B | 371.81% |
| Mar 31, 2023 | 451.32M | 204.15M | 82.59% |
| Mar 31, 2022 | 247.17M | 59.09M | 31.42% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accent Microcell | 3.56B |
| Infinium Pharmachem | 1.57B |
| Zenith Drugs | 1.44B |
| Quest Laboratories | 1.26B |
| Sotac Pharmaceuticals | 846.72M |
| Sunrest Lifescience | 520.34M |
| Medicamen Organics | 394.30M |
| Vilin Bio Med | 199.81M |